Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatneik J, Miller SM. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement. 2011;7:532–9. https://doi.org/10.1016/J.JALZ.2011.05.2410
Atri A. The Alzheimer’s disease clinical spectrum: diagnosis and management. Med Clin North Am. 2019;103:263–93. https://doi.org/10.1016/J.MCNA.2018.10.009
Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of early Alzheimer’s disease: clinical practice in 2021. J Prev Alzheimers Dis. 2021;8:371–86. https://doi.org/10.14283/JPAD.2021.23
Article CAS PubMed Google Scholar
Knopman DS, Amieva H, Petersen RC, Chetelat G, Holtzman DM, Hyman BT, Jones DT. Alzheimer disease. Nat Rev Dis Primers. 2021;7:33. https://doi.org/10.1038/S41572-021-00269-Y
Article PubMed PubMed Central Google Scholar
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8:595–608. https://doi.org/10.15252/EMMM.201606210
Article CAS PubMed PubMed Central Google Scholar
Kumar A, Singh A, Ekavali. A review on Alzheimer’s disease pathophysiology and its management: An update. Pharmacol. Rep. 2015;67:195–203. https://doi.org/10.1016/j.pharep.2014.09.004
Article CAS PubMed Google Scholar
Deture MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14:32. https://doi.org/10.1186/S13024-019-0333-5
Article PubMed PubMed Central Google Scholar
Kametani F, Hasegawa M. Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer’s disease. Front Neurosci. 2018;12:25. https://doi.org/10.3389/FNINS.2018.00025
Article PubMed PubMed Central Google Scholar
Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Frolich L, Dubois B. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017;9:60. https://doi.org/10.1186/S13195-017-0283-5
Article PubMed PubMed Central Google Scholar
Zhang H, Ma Q, Zhang YW, Xu H. Proteolytic processing of Alzheimer’s β-amyloid precursor protein. J Neurochem. 2012;120:9–21. https://doi.org/10.1111/J.1471-4159.2011.07519.X
Article CAS PubMed Google Scholar
Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonesca J, Taghva K Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement. 2022;8:e12295. https://doi.org/10.1002/TRC2.12295
Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. 2020. Alzheimer’s disease drug development pipeline: 2020. Alzheimers and Dement. 2020;6:e12050. https://doi.org/10.1002/trc2.12050
Sevigny J, Chiao P, Bussière T. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537:50–56. https://doi.org/10.1038/nature19323
Article CAS PubMed Google Scholar
Salloway S, Chalkias S, Barkhof F, Barakos J, Purcell D, Suhy J, Smirnakis K. Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79:13–21. https://doi.org/10.1001/JAMANEUROL.2021.4161
Van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Iwatsubo T. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:142–3. https://doi.org/10.1056/NEJMOA2212948
Reardon S. Alzheimer’s drug donanemab: what promising trial means for treatments. Nature. 2023;617:232–3. https://doi.org/10.1038/D41586-023-01537-5
Article CAS PubMed Google Scholar
Makurvet FD. Biologics vs. small molecules: Drug costs and patient access. Med Drug Discov. 2021;9:100075. https://doi.org/10.1016/J.MEDIDD.2020.100075
Mohamed T, Yeung JCK, Vasefi MS, Beazely MA, Rao PPN. Development and evaluation of multifunctional agents for potential treatment of Alzheimer’s disease: Application to a pyrimidine-2,4-diamine template. Bioorg Med Chem Lett. 2012;22:4707–12. https://doi.org/10.1016/j.bmcl.2012.05.077
Article CAS PubMed Google Scholar
Mohamed T, Shakeri A, Tin G, Rao PPN. Structure-activity relationship studies of isomeric 2,4-diaminoquinazolines on β-amyloid aggregation kinetics. ACS Med Chem Lett. 2016;7:502–7. https://doi.org/10.1021/acsmedchemlett.6b00039
Article CAS PubMed PubMed Central Google Scholar
Mohamed T, Shakeri A, Rao PPN. Amyloid cascade in Alzheimer’s disease: recent advances in medicinal chemistry. Eur J Med Chem. 2016;113:258–72. https://doi.org/10.1016/J.EJMECH.2016.02.049
Article CAS PubMed Google Scholar
Sashidhara KV, Kumar M, Modukuri RK, Sonkar R, Bhatia G, Khanna AK, Shukla R. Synthesis and anti-inflammatory activity of novel biscoumarin–chalcone hybrids. Bioorg Med Chem Lett. 2011;21:4480–4. https://doi.org/10.1016/j.bmcl.2011.06.002
Article CAS PubMed Google Scholar
Kim MJ, Lee YH, Kwak J, Na Y, Yoon HG. Protective effects of a chalcone derivative against Aβ-induced oxidative stress and neuronal damage. BMB Rep. 2011;44:730–4. https://doi.org/10.5483/BMBREP.2011.44.11.730
Article CAS PubMed Google Scholar
Cao Z, Yang J, Xu R, Song Q, Zhang X, Liu H, Deng Y. Design, synthesis and evaluation of 4’-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer’s disease treatment. Bioorg Med Chem. 2018;26:1102–15. https://doi.org/10.1016/J.BMC.2018.01.030
Article CAS PubMed Google Scholar
Liu HR, Liu XJ, Fan HQ, Tang JJ, Gao XH, Liu WK. Design, synthesis and pharmacological evaluation of chalcone derivatives as acetylcholinesterase inhibitors. Bioorg Med Chem. 2014;22:6124–33. https://doi.org/10.1016/J.BMC.2014.08.033
Article CAS PubMed Google Scholar
Jackson PA, Widen JC, Harki DA, Brummond KM. Covalent modifiers: a chemical perspective on the reactivity of α,β-unsaturated carbonyls with thiols via hetero-Michael addition reactions. J Med Chem. 2017;60:839–85. https://doi.org/10.1021/ACS.JMEDCHEM.6B00788
Article CAS PubMed Google Scholar
Zhuang C, Zhang W, Sheng C, Zhang W, Xing C, Miao Z. Chalcone: a privileged structure in medicinal chemistry. Chem Rev. 2017;117:762–7810. https://doi.org/10.1021/acs.chemrev.7b00020
Baell J, Walters MA. Chemistry: chemical con artists foil drug discovery. Nature. 2014;513:481–3. https://doi.org/10.1038/513481A
Article CAS PubMed Google Scholar
Baell JB. Redox-active nuisance screening compounds and their classification. Drug Discov Today. 2011;16:840–1. https://doi.org/10.1016/j.drudis.2011.06.011
Burgos-Morón E, Calderón-Montaño JM, Salvador J, Robles A, Lazaro ML. The dark side of curcumin. Int J Cancer. 2010;126:1771–5. https://doi.org/10.1002/IJC.24967
Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53:2719–40. https://doi.org/10.1021/JM901137J
留言 (0)